Meeting
2015 ASCO Annual Meeting
Phase I study of temsirolimus in combination with cetuximab in patients with advanced solid tumors.
Authors
Antoine Hollebecque
Drug Development Department, Gustave Roussy, Cancer Campus, Grand Paris, Villejuif, France
Antoine Hollebecque , Rastislav Bahleda , Jean Christophe Thery , Laura Faivre , Marie-Cécile Le Deley , Angelo Paci , Andrea Varga , Anas Gazzah , Christophe Massard , Vianney Poinsignon , Katty Malekzadeh , Vincent Ribrag , ERIC ANGEVIN , Sophie Postel-Vinay , Carlos Alberto Gomez-Roca , Myriam Gharib , Fabienne Dufour , Jean-Charles Soria , Jean-Philippe Spano
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Signal Transduction
Clinical Trial Registration Number
NCT02215720
Citation
J Clin Oncol 33, 2015 (suppl; abstr 2599)
DOI
10.1200/jco.2015.33.15_suppl.2599
Abstract #
2599
Poster Bd #
315
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
A phase I study of temsirolimus plus erlotinib in patients with refractory solid tumors.
First Author: Andrea Wang-Gillam
Poster
2021 ASCO Annual Meeting
Final results of phase 1 evaluation of the safety and clinical activity of sapanisertib in combination with serabelisib and paclitaxel in patients with advanced ovarian, endometrial, or breast cancer.
First Author: David Starks
Poster
2016 ASCO Annual Meeting
Phase I dose-escalation trial of Sym004, a mixture of two anti-EGFR antibodies, in Japanese patients with advanced solid tumors.
First Author: Ken Kato
Poster
2015 ASCO Annual Meeting
A phase I, first-in-human dose study of the dual PI3K/mTOR inhibitor LY3023414 (LY) in patients (pts) with advanced cancer.
First Author: Kathleen N. Moore